## Remarks

Claims 22 and 23 have been canceled without prejudice to the filing of continuing applications.

The claims stand rejected under 35 U.S.C. §112, first paragraph, for failing to comply with the written description requirement. Accordingly, the claims have been amended as suggested by the Examiner by replacing "oligoribonucleotide" at every instance with "ribozyme". Withdrawal of the rejection is therefore respectfully requested. In addition, the cancellation of claims 22 and 23 renders moot the rejection of the same under 35 U.S.C. §112, first paragraph, as failing to comply with the enablement requirement.

Allowance of the claims and passage of the case to issue is respectfully solicited. Should the Examiner believe a discussion of this matter would be helpful, she is invited to telephone the undersigned at (312) 913-0001.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: April 18, 2007 By:

Stephen H. Docter

Registration No. 44,659